VBI Vaccines Inc VBIV
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if VBIV is a good fit for your portfolio.
News
-
VBI Vaccines Announces Results of Annual General Meeting
-
VBI Vaccines Announces New Tumor Response Data from Ongoing Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma Patients
-
VBI Vaccines Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma Patients
-
VBI Vaccines Reports First Quarter 2024 Financial Results
Trading Information
- Previous Close Price
- $0.54
- Day Range
- $0.53–0.57
- 52-Week Range
- $0.45–1.36
- Bid/Ask
- $0.53 / $0.60
- Market Cap
- $16.06 Mil
- Volume/Avg
- 95,521 / 151,753
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.16
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
VBI Vaccines Inc is a commercial-stage, the biopharmaceutical company which is engaged in developing next-generation vaccines to address unmet needs in infectious disease and immuno-oncology. The company manufactures Sci-B-Vac product which is a hepatitis B (HBV) vaccine for adults, children, and newborns. Its products include Virus-Like Particle which is vaccine platform which allows for the design of enveloped virus-like particle vaccines that closely mimic the target viruses. The company operates through the single segment being Developing vaccines to address unmet needs in infectious disease and immuno-oncology.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 138
- Website
- https://www.vbivaccines.com
Valuation
Metric
|
VBIV
|
---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 1.16 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric
|
VBIV
|
---|---|
Quick Ratio | 0.18 |
Current Ratio | 0.34 |
Interest Coverage | −9.35 |
Quick Ratio
VBIV
Profitability
Metric
|
VBIV
|
---|---|
Return on Assets (Normalized) | −51.28% |
Return on Equity (Normalized) | −325.07% |
Return on Invested Capital (Normalized) | −62.93% |
Return on Assets
VBIV
Biotechnology Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Novo Nordisk A/S ADR
NVO
| Jqgxjvmksj | Zhbh | $565.6 Bil | |||
Vertex Pharmaceuticals Inc
VRTX
| Zcpjdmz | Mcpcxvz | $127.8 Bil | |||
Regeneron Pharmaceuticals Inc
REGN
| Cqgqmcgj | Ysfvkl | $118.7 Bil | |||
Moderna Inc
MRNA
| Rhkrdjmrn | Wtfh | $46.8 Bil | |||
Alnylam Pharmaceuticals Inc
ALNY
| Ylnsmyjp | Pwcnxmv | $29.7 Bil | |||
argenx SE ADR
ARGX
| Nkqgbfhnl | Nqxp | $29.3 Bil | |||
BioNTech SE ADR
BNTX
| Wlbvprmpl | Bzqt | $20.7 Bil | |||
Biomarin Pharmaceutical Inc
BMRN
| Bpwbnnn | Sgwkvv | $16.1 Bil | |||
United Therapeutics Corp
UTHR
| Lggwghv | Wqryh | $15.0 Bil | |||
Incyte Corp
INCY
| Gtjrfqzp | Jsrpkf | $13.5 Bil |